The compendium of newly emerging and currently available hemophilia and anticoagulant treatments, while offering new choices for improved patient care, can create significant levels of interference with routine and specialized laboratory coagulation assays. Our new educational session will examine the interference in coagulation tests from presence of the direct oral anticoagulants (DOACs) and the extended half-life (EHL) and non-factor products. It is important for laboratories to be aware of how both classes of these products, when present, can impact downstream results and clinical decision making.
Upon completion of this session, participants will be able to:
1. Identify how to detect DOAC’s with routine coagulation tests and how they impact results.
2. Understand how the new EHL products for hemophilia A and B perform in relation to the laboratory’s coagulation reagents.
3. Increase awareness of the impact of these issues on coagulation testing.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety. CE credits are available for this webinar up to 2 years from the date of the live broadcast
Laboratory Testing
Hematology
Clinical Diagnostics
Immunology
Clinical Chemistry
Microbiology
Infectious Disease
Molecular Diagnostics
Molecular Biology
Biochemistry
Diagnostics
Clinical Research
Genetics
Cancer Research
Medicine
North America84%
Asia7%
Europe6%
South America1%
Oceania1%
Africa1%
Website Visitors60%
Email Promotions32%
WAVE Newsletter Promotion5%
Website Banners1%
Trending Newsletter Promotion1%
Other1%
Medical Laboratory Technician32%
Clinical Laboratory Scientist20%
Lab Management14%
Facility/Department Manager8%
Medical Doctor/Specialist7%
Educator/Faculty5%
Student4%
Executive4%
QC/QA2%
Scientist2%
Research Scientist2%
Pathologist1%
Hospital41%
Clinical Laboratory20%
Academic Institution10%
Medical Center4%
Government3%
Biotech Company3%
Medical Device Company2%
Diagnostic Company1%
Ambulatory Care1%
General Laboratory1%
Physician Office Laboratory1%
Research Institute1%
Government/public1%
Independent Laboratories1%
Other2%